Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Aprepitant · Aponvie, Cinvanti

Small molecule · Antagonist of substance P/neurokinin 1 (NK1) receptor (TACR1) · developed by Msd

Approved FDA, Mar 2003
3 Registered trials

What is Aprepitant?

Aprepitant is a selective, high-affinity antagonist of the substance P/neurokinin 1 (NK1) receptor that crosses the blood-brain barrier and acts centrally. It is studied for and used in the prevention of nausea and vomiting, including chemotherapy-induced and postoperative nausea and vomiting.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Aponvie, Cinvanti, Emend, MK-0869, MK-869
Drug type
Small molecule
Targets
substance P/neurokinin 1 (NK1) receptor (TACR1)
Mechanism
Antagonist of substance P/neurokinin 1 (NK1) receptor (TACR1)
Pathways
substance P signaling, emesis (central nervous system)
Therapy area
Infectious disease, Respiratory
Developer
Msd
In trials of
HRTX
FDA status
Approved as Aponvie, Cinvanti, Emend (March 26, 2003), NDA021549 · FDA label
UNII
1NF15YR6UY

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 1, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07639723 Phase 4 PONV Not yet recruiting HRTX
NCT04470622 Phase 2 COVID-19 Terminated HRTX
NCT03718039 Phase 2 Postoperative Pain Completed HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PONVCOVID-19Postoperative Pain

Other drugs acting on TACR1

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.